Aim: To examine the association between early onset of type 2 diabetes mellitus (DM) and clinical and behavioural risk factors for later complications of diabetes.
| Data collection
Enrolment in the DD2 cohort has previously been described by Nielsen et al. 21 In brief, patients are diagnosed with type 2 DM in everyday routine clinical practice-either by hospital physicians or general practitioners-and are thereafter invited to participate in the DD2 project. In both settings, the diagnostic criteria have followed Danish national guidelines and World Health Organization criteria throughout the study period. If a patient gives informed consent to participate, the physician may choose to perform the DD2 enrolment procedures himself or may refer the patient to a hospital outpatient clinic, where all procedures are performed. Upon enrolment, an online registration form 21 containing patient-reported and clinical examination data is completed. Fasting urine and blood samples are obtained and then stored in the DD2 biobank.
The unique Central Personal Registration number provided to all Danish residents at birth or upon immigration is used to link DD2 data with Danish national health registries. In our study, these included (1) the Danish National Prescription Registry, containing individual-level information on prescriptions dispensed from all Danish community pharmacies; (2) the Danish National Patient Registry, containing information on hospital inpatient and outpatient clinic contacts; and (3) the Danish Diabetes Database for Adults (DDDA), a nationwide quality-ofcare database containing indicators for adults with diabetes reported from general practices and hospital outpatient clinics. 22 Supplementary data sources in the DD2 have been described by Thomsen et al. 22 Fasting glucose was measured as a part of the enrolment procedure. Information on HbA1c was collected from the DDDA, using the HbA1c value measured closest to the DD2 enrolment date. The chosen cut point for increased LDL cholesterol at 2.5 mmol/L is the Danish recommended threshold for initiating lipid-lowering treatment. 23 We defined the presence of any dyslipidemia according to the American Diabetes Association 
| Statistical analysis
Prevalence proportions were estimated for categorical variables.
Medians with interquartile ranges were calculated for continuous variables, as data were not normally distributed. To compare prevalence in different age groups, prevalence ratios (PRs) with 95% confidence intervals (95% CIs) were calculated by using Poisson regression analysis. The average-onset group (diagnosis at age 56-65 years) was used as the reference group. For many patients, the first prescription of a glucose lowering drug (GLD) had been made several months before enrolment into the DD2 cohort. Moreover, the treatment duration before enrolment varied across age groups ( 
| Glucose control
We observed a clear gradient of increasingly poor glucose control in members of the younger-onset groups, after adjusting for duration of glucose-lowering treatment before enrolment ( with higher glucose levels in younger age groups, was observed for fasting plasma glucose ( Figure 1B ).
| Other clinical risk factors
In the early-onset group, 39% had BMI >35, 9 in 10 had central obesity (88%), one third had hypertension (32%), and close to half had a LDL >2.5 mmol/L (50%) and CRP >3.0 mg/L (53%) ( Table 2 ).
The prevalence of hospital-diagnosed retinopathy was also higher in the early-onset group (7%) than in the average-onset group (5%) (PR Figure 1D ). Figure 1F ). There was also a gradient in prevalence of daily smoking; 24%, 20%, and 8% in the early-, average-, and late-onset groups, respectively (PR 1.18
| Behavioural risk factors
[95% CI 0.98, 1.42] and PR 0.39 [95% CI 0.27, 0.56]) (Table 3 and Figure 1F ). Self-reported high-risk alcohol intake was below 10% in all age groups and lower in the early-onset (4%) than in the averageonset (7%) group (PR 0.50 [95% CI 0.31, 0.81]) (Table 3 ).
| Therapy
Between 75% and 80% of persons in the five age-of-onset groups received noninsulin GLDs at time of cohort enrolment ( (Table 4 and Figure 1G ). Insulin use was higher (21%) among GAD antibody positive cohort members than among the GAD antibody negative members (7%), but the finding of higher insulin use in the early-onset group remained when excluding GAD antibody positive individuals (data not shown). In the early-onset group, 40% received antihypertensive drugs, 53% received lipid-lowering drugs, and 8% received anticoagulation drugs. Use of all three drug types increased with age of onset ( Figure 1H ).
The key finding in this study was an age gradient of increasingly higher prevalence of most clinical and behavioural risk factors with younger age at type 2 DM diagnosis. Persons with early-onset type 2 DM had a markedly higher prevalence of severe obesity, dyslipidemia, low-grade inflammation, tobacco smoking, and physical inactivity. Importantly, persons in the early-onset group also had poorer glucose control than persons in the later-onset groups, although the early-onset individuals were more likely to receive both insulin and noninsulin glucose lowering treatment. Retinopathy and microalbuminuria were present at worrisome levels among persons with early-onset type 2 DM in light of their short disease duration and young age.
Previous studies corroborate clustering of risk factors in persons with newly diagnosed early-onset type 2 DM. A US study 18 Prevalence of risk factors for diabetes related complications among 5115 people with newly diagnosed type 2 diabetes in 5 groups defined by age at diagnosis higher likelihood of receiving any GLD, and a 3.6-fold higher likelihood of receiving several GLDs, within the first year. 27 Two large cohort studies 28, 29 in Danish background populations identified an age-gradient with higher prevalence of hypertension in older individuals. When comparing these findings with the prevalence found in our study (~30% with hypertension in all age groups), the prevalence of hypertension among the early-onset individuals was higher than in a similar-aged background population, whereas the prevalence among the late-onset individuals was lower than in a similar-aged background population.
Health behaviour is likely to contribute to the observed adverse clinical profile of the early-onset group. A large cross-sectional study Estimates are shown as percentages (%), medians (m) with interquartile ranges (IQR), or prevalence ratios (PR) with 95% confidence Intervals (95% CI).
*Adjusted for time since commencement of glucose-lowering pharmacological treatment to enrolment in the DD2 cohort. found a lower physical activity level among persons with early-onset type 2 DM than among those with later-onset type 2 DM. 16 The smoking prevalence of 24% in the early-onset group in our study was not only higher than in the later-onset groups but is also higher than the Danish national average of 18% in a similar age group (35-44 years) 30 . Similarly, in the United States, smoking prevalence Gregg et al. 12 showed that the overall improvements in diabetes outcomes observed during the last 20 years are primarily due to a reduction in complications among older persons with type 2 DM. Therefore, the increased incidence of type 2 DM in high-risk young persons could cause a future rise in diabetes complications. 12 
| Strength and limitations
The main strength of our study was the comprehensiveness of uniformly collected data in a large incident cohort of persons clinically diagnosed with type 2 DM. The linkage of clinical and self-reported information with data from high-quality national health registers allowed for a full description of risk factors. For some risk factors, such as anthropometric measures and laboratory values, there were missing data, and missing data were somewhat more common in the elderly than younger age groups in our cohort (data not shown). A slightly lower completeness of risk factor values by older age would not necessarily bias our findings, unless completeness was related both to age and to the actual value of the data, which we find less likely.
Availability of laboratory values was related to calendar period of data in the biobank, not to age group.
The cross-sectional study design is an inborn limitation, as it implies uncertainty regarding how the risk factors preceded each other, and impedes knowledge about the development over time in risk profiles. Moreover, there is an over-representation of persons with type 2 DM receiving hospital-based versus primary care in the DD2 cohort. Consequently, since both young age and a high risk-factor level in type 2 DM may lead to referral from GP to outpatient hospital care, relatively more high-risk individuals may have been recruited into the cohort among early-than among later-onset type 2 DM individuals, leading to a Berkson-like bias and a possible overestimation of risk factor prevalence in the early-onset group.
| CONCLUSION
In conclusion, our study identified an increasing prevalence of clinical and behavioural risk factors the younger the onset age of type 2 DM, emphasizing that early-onset type 2 DM is not a benign condition. Our results underline the need for clinical awareness and multifactorial interventions among early-onset type 2 diabetes patients and a need for prospective studies exploring the association between early risk factors and development of diabetes-related complications.
